Journal
WIENER MEDIZINISCHE WOCHENSCHRIFT
Volume 165, Issue 11-12, Pages 217-228Publisher
SPRINGER WIEN
DOI: 10.1007/s10354-015-0360-y
Keywords
Evidence-based phytotherapy; Elderly; Anxiety/depression/dementia; Randomized controlled trials
Categories
Funding
- Eli Lilly
- Lundbeck
- Bristol-Myers Squibb
- GlaxoSmithKline
- Organon
- Sepracor
- Servier
Ask authors/readers for more resources
Based on subgroup analyses of randomized, controlled clinical trials, we review the efficacy of three phytopharmaceutical drugs, respectively of the corresponding active substances silexanA (R) (WSA (R) 1265, lavender oil) in anxiety disorders, WSA (R) 5570 (Hypericum extract) in major depression, and EGb 761A (R) (Ginkgo biloba extract) in Alzheimer, vascular, or mixed type dementia, in elderly patients aged a parts per thousand yenaEuro parts per thousand 60 years. Four trials were eligible in each indication. Meta-analyses and analyses based on pooled raw data showed that the three drugs were significantly superior to placebo in the elderly subset, and that their treatment effects reflected in the main outcome measures (Hamilton Anxiety scale, Hamilton Depression scale, Neuropsychiatric Inventory) were comparable with those observed in the original trials without age restrictions. The results confirm the efficacy of the three herbal active substances in elderly patients of a parts per thousand yenaEuro parts per thousand 60 years of age. In anxiety, depression, and dementia, they thus represent efficacious and well-tolerated alternatives to synthetic drugs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available